ライフサイエンスコーパス: PK

1 PK analysis demonstrated a 2.2-fold increase in glecapre

2 PK and FXII undergo reciprocal conversion to their activ

3 PK data demonstrated a dose-dependent increase in plasma

4 PK modeling predicts that the gastroretentive formulatio

5 PK-LRR and SA mediated disease resistance are well known

6 PK/PD assessments of edoxaban included endogenous and ex

7 PK/PD/behavioral findings support continued research of

8 8 of whom underwent both 18F-AV-1451 and 11C-PK-11195 PET, and matched control subjects (14 for 18F-A

9 as a strong positive correlation between 11C-PK-11195 and 18F-AV-1451 uptake in all disease groups, a

10 subjects (14 for 18F-AV-1451 and 15 for 11C-PK-11195).

11 We used PET in vivo with (i) 11C-PK-11195, a marker of activated microglia and a proxy in

12 nd significant group-wise differences in 11C-PK-11195 binding between each patient group and controls

13 The multivariate distribution of 11C-PK-11195 binding related better to clinical heterogeneit

14 During the study period, 1676 PKs and 2292 EKs for 3069 patients were performed.

15 Among 42 PK-evaluable women from 5 African countries, median age

16 s across preclinical species, resulting in a PK profile suitable for long-acting parenteral administr

17 e, it also demonstrated CNS penetration in a PK study and significant reduction of parasitemia in fou

18 ully fitted plasma CAB concentrations into a PK model (R(2) = 0.9999) and determined CAB apparent eli

19 uced the conversion of the mutated C1 into a PK-resistant and infectious form perpetuating the bioche

20 ptimization of this chemical cleavage acDrug PK assay, resulting in robust accuracy and precision (+/

21 We developed acDrug PK assays for next-generation disulfide-linked ADCs invo

22 However, robust acDrug PK methods for disulfide-linked self-immolating ADCs are

23 FT-2102 has excellent ADME/PK properties and reduces 2-hydroxyglutarate levels in a

24 Eyes with endophthalmitis after PK had poorer visual acuity outcomes and graft prognosis

25 the odds of developing endophthalmitis after PK or EK performed in conjunction with anterior vitrecto

26 d did not return to normal values even after PK.

27 ; 12 cases of endophthalmitis occurred after PK and 4 cases occurred after EK.

28 Visual acuity outcomes were poorer after PK-related endophthalmitis than EK-associated cases (P =

29 .2%) was significantly lower than that after PK (12 of 1676; 0.7%) (P = .01).

30 Altered PK, and excretion profiles of acetaminophen were observe

31 ival of 94.7%, compared to DSAEK (65.1%) and PK (47.0%, P = .001).

32 vival of 98.7% compared to DSAEK (96.2%) and PK (73.5%) (P = .009).

33 d down expression of KRAS in human (PK-8 and PK-1) PDAC cells with small hairpin RNAs.

34 d intraocular pressure compared to DSAEK and PK for the same indications.

35 better graft survival compared to DSAEK and PK.

36 n initiate reciprocal activation of FXII and PK in solution or on a surface.

37 r between the MCD (11.25 +/- 1.69 mm Hg) and PK (12.0 +/- 2.67 mm Hg) groups (P = .95); however, the

38 nhibitors displaying exceptional potency and PK properties.

39 59 were associated with favorable safety and PK profiles.

40 ents while balancing metabolic stability and PK properties allowing for clinically relevant exposures

41 hy coupled with mass-spectroscopy (UPLC) and PK parameters were calculated using noncompartmental met

42 cutive primary grafts of DALKs (n = 362) and PKs (n = 307) performed for optical indications in a ter

43 Two distinct isozymes of bacterial PK have been recognized, PykA and PykF.

44 to compare long-term graft survival between PK and DALK.

45 hrs for PECAM), despite having similar blood PK, indicating that binding strength is more important p

46 was predicted by the model and confirmed by PK data.

47 ion cleavage site (PK-R371A, or single-chain PK).

48 ry good fit to individual time-concentration PK profiles and concluded that inter-subject differences

49 Conjugate PK assay strategies for these ADCs involve cleavage with

50 netics, safety, tolerability, dose-dependent PK/PD relationships and high clinical potential for the

51 peline of candidates positioned for detailed PK/PD and pre-clinical evaluation.

52 Deterministic PK models input host and product factors and output spat

53 DNA-PK and the cNHEJ pathway play important roles in the DNA

54 DNA-PK autophosphorylates DNA-PKcs, which is its best charac

55 DNA-PK deficiency reduces cGAS phosphorylation and promotes

56 DNA-PK has therefore been pursued for the development of ant

57 DNA-PK inhibition reduces the ability of E4orf4 to induce ca

58 DNA-PK inhibitors have the potential to block DNA repair and

59 DNA-PK is a key component within the DNA damage response, as

60 DNA-PK, but not other cNHEJ factors, resides in nucleoli in

61 est a new mechanism for NHEJ utilizing a DNA-PK dimer to bring broken DNA ends together.

62 M3814 is a DNA-PK inhibitor that has shown preclinical activity in comb

63 Activated DNA-PK phosphorylates DNA-PKcs at the S2056 and T2609 cluste

64 s to DNA ends and recruits and activates DNA-PK.

65 In conclusion, we identified PTEN and DNA-PK as essential regulators of replication checkpoint arr

66 nned DNA ends robustly stimulate certain DNA-PK autophosphorylations.

67 Delayed DNA-PK inhibition greatly contributes to Ad replication effi

68 support an important role for the E4orf4-DNA-PK interaction in Ad replication and in facilitation of

69 For DNA-PK, all existing structures represent inactive states wi

70 DNA-dependent protein kinase holoenzyme (DNA-PK) in the process of non-homologous end joining (NHEJ).

71 ciated with autoimmune diseases, yet how DNA-PK deficiency leads to increased immune responses remain

72 block the Ku-DNA interaction and inhibit DNA-PK kinase activity.

73 protein kinase (DNA-PK), which inhibits DNA-PK function and causes amplification of irradiation- and

74 es of the DDR, whereas it later inhibits DNA-PK itself.

75 identified DNA-dependent protein kinase (DNA-PK) as a cGAS-independent and alternative DNA cytosolic

76 coding the DNA-dependent protein kinase (DNA-PK) catalytic subunit (DNA-PKcs) are associated with aut

77 DNA-dependent protein kinase (DNA-PK) has been shown to play a crucial role in repair of D

78 The DNA-dependent protein kinase (DNA-PK) is a cNHEJ factor that encompasses the Ku70-Ku80 (KU

79 DNA-dependent protein kinase (DNA-PK) is a critical player in the DNA damage response (DDR

80 DNA-dependent protein kinase (DNA-PK) plays a critical role in the non-homologous end join

81 plies, the DNA dependent protein kinase (DNA-PK) requires DNA double-stranded ends for enzymatic acti

82 DNA-dependent protein kinase (DNA-PK), like all phosphatidylinositol 3-kinase-related kina

83 3beta) and DNA-dependent protein kinase (DNA-PK), respectively.

84 The DNA-dependent protein kinase (DNA-PK), which comprises the KU heterodimer and a catalytic

85 binding to DNA-dependent protein kinase (DNA-PK), which inhibits DNA-PK function and causes amplifica

86 The DNA-dependent protein kinase (DNA-PK), which is composed of the KU heterodimer and the lar

87 cGAS-independent and DNA-protein kinase (DNA-PK)-dependent manner.

88 3 (GOLPH3)-DNA-dependent protein kinase (DNA-PK)-myosin XVIIIA-F-actin signaling pathway.

89 n and RNF138-dependent removal of the Ku/DNA-PK complex, is better able to predict levels of repair s

90 Ku70-Ku80 (KU) heterodimer and the large DNA-PK catalytic subunit (DNA-PKcs).

91 We also report a cryo-EM structure of DNA-PK at 3.5- angstrom resolution and reveal a dimer mediat

92 sphorylation of the catalytic subunit of DNA-PK at serine 2056 in response to IR or etoposide treatme

93 ures reveal the sequential transition of DNA-PK from inactive to activated forms.

94 e report the discovery of a new class of DNA-PK inhibitors that act via a novel mechanism of action,

95 Deletion of DNA-PK or PTEN, or inhibition of DNA-PK sensitized recoverin

96 tion of DNA-PK or PTEN, or inhibition of DNA-PK sensitized recovering BLBCs to AZD1775 by abrogating

97 AZD1775 induced phosphorylation of DNA-PK, protecting cells from replication-associated DNA dam

98 f is the best-characterized substrate of DNA-PK.

99 chemical inhibitors for ATR, ATM, and/or DNA-PK.

100 oscopy (cryo-EM) structures of DNA-PKcs (DNA-PK catalytic subunit) bound to a DNA end or complexed wi

101 U3 activates purified DNA-PK and triggers phosphorylation of DNA-PKcs at T2609.

102 Early during infection, E4orf4 requires DNA-PK activity to inhibit various branches of the DDR, wher

103 ate that the potent and highly selective DNA-PK inhibitor, AZD7648, is an efficient sensitizer of rad

104 rf4 interacts with the DNA damage sensor DNA-PK in a biphasic manner.

105 Here we use mouse models to show that DNA-PK has an unexpected role in the biogenesis of ribosomal

106 Together our data show that DNA-PK has RNA-dependent, cNHEJ-independent functions during

107 In this study, we report that DNA-PK phosphorylates cGAS and suppresses its enzymatic acti

108 hallenging to identify inhibitors of the DNA-PK catalytic subunit (DNA-PKcs) with good selectivity ve

109 (whether deficient in components of the DNA-PK complex or components of the ligase complex) are simi

110 cluster are robustly phosphorylated when DNA-PK is activated by hairpinned DNA ends.

111 he Artemis nuclease that associates with DNA-PK to mediate hairpin opening.

112 Dox PK was described with a two-compartment model and tumor

113 temporal heterogeneity of intralesional drug PK, have major implications for antimicrobial drug devel

114 in animals are often not predictive of drug PKs and PDs in humans, and in vitro PK and PD modelling

115 Gene edited PK-15 cell lines were used to show the dsRNA-sensing pat

116 were significantly higher than after either PK or EK alone (odds ratio 8.66; 95% confidence interval

117 s large cohort of patients undergoing either PK or EK, rates of endophthalmitis were low for both pro

118 iral potency in cell culture and encouraging PK properties.

119 ctive CHIT1 inhibitor with both an excellent PK profile in multiple species and selectivity against a

120 on: Included were all patients with a failed PK graft who underwent either F-DMEK (10 eyes of 10 pati

121 is a safe and effective procedure in failed PK patients, with outcomes comparable to M-DMEK, and wit

122 ts was 33.1 +/- 10.13 years; indications for PK were herpetic corneal scar (53.3%), corneal stromal d

123 The LOQ for PK, MK-4 and MK-7 was 0.5 ug/100 g food, while for MK-9

124 early results similar to those published for PK in a multisurgeon setting.

125 The survival rate for PK was 94.4%, 80.4%, and 72.0% at 1, 5, and 10 years, re

126 tivity procedure, and gave blood samples for PK/PD testing.

127 al for primary DALK was superior to that for PK for corneal pathologies with functional endothelium.

128 For grafts intended for PKs, antifungal supplementation was less cost-effective

129 strained to the single-chain precursor form, PK-R371A cleaves high-molecular-weight kininogen (HK) to

130 d ABO blood group status can influence FVIII PK, they do not account for all observed variability.

131 clearance and ABO glycosylation modify FVIII PK in a pediatric population.

132 blood group, is a strong regulator of FVIII PK.

133 WF and FVIII, were associated with the FVIII PK profile.

134 Within-group PK parameters were consistent.

135 /- 2 ml) was observed; SA (18.22 g; 91.1%) > PK (17.32 g; 86.6%) > I (16.33 g; 81.65%).

136 on (ng/ml) in the samples as; SA, 34410.36 > PK, 7778.95 > I, 4106.43.

137 ental analysis revealed an order of SA > I > PK for tested elements.

138 em-loop helix (P1) and the pseudoknot helix (PK).

139 On day 28, 24-hour PK sampling was undertaken.

140 nical data are available, the observed human PK are compared with predictions, providing an opportuni

141 Here, we discuss methods to predict human PK used by AstraZeneca, how these predictions are assess

142 We knocked down expression of KRAS in human (PK-8 and PK-1) PDAC cells with small hairpin RNAs.

143 n of MTM as an effective strategy to improve PK.

144 ntagonise Sendai virus-mediated apoptosis in PK-15 cells.

145 concluded that inter-subject differences in PK parameters was the lowest for irinotecan, intermediat

146 There were no significant differences in PK/PD assessment of edoxaban in patients with versus wit

147 ivering high plasma concentrations of PIB in PK studies conducted in mice, dogs, and monkeys.

148 dels to analyse inter-patient variability in PK parameters.

149 ved by extracellularly applied proteinase K (PK), an N-terminal truncation up to amino acid residue 2

150 e mutant cells stably produced proteinase K (PK)-resistant, insoluble, and aggregated assemblies that

151 All penetrating keratoplasties (PK) performed at the Singapore National Eye Centre (SNEC

152 and conversion to penetrating keratoplasty (PK) and the percentage of patients, post removal of sutu

153 were converted to penetrating keratoplasty (PK) intraoperatively.

154 were converted to penetrating keratoplasty (PK).

155 patients underwent penetrating keratoplasty (PK).

156 e graft failure in penetrating keratoplasty (PK).

157 atoplasty (EK) and penetrating keratoplasty (PK); amphotericin B, voriconazole, caspofungin, and comb

158 the clinic with no PK issues; and 71% of key PK parameter predictions [64% of area under the curve (A

159 LDH/PK and colorimetric enzymatic assays revealed two promis

160 unction for the FXII HC that normally limits PK activation in plasma.

161 CLDN-2 silencing in LLC-PK(1) tubular cells induced activation and phosphorylati

162 d and evaluated a site-of-action mechanistic PK model using nonlinear mixed effects methodology.

163 It was connected to semi-mechanistic PK models to analyse inter-patient variability in PK par

164 In a mouse PK/PD model, oral dosing of lead compound 2 demonstrated

165 The druglike characteristics and mouse PK data are described along with the X-ray crystal struc

166 asma and tumor tissues from a low-dose mouse PK study.

167 MPA PK parameters were calculated using noncompartmental ana

168 ment projects progress in the clinic with no PK issues; and 71% of key PK parameter predictions [64%

169 The highest amount of PK was detected in kimchi (42 ug/100 g), whereas the hig

170 Deficiency or pharmacologic blockade of PK renders mice less susceptible to experimental autoimm

171 larity, which is partly due to the degree of PK variability.

172 M2 isoform (tM2-PK), which is an isoform of PK-glycolytic enzyme and appears on the surface of cance

173 the unbinding pathway for different poses of PK-11195, a TSPO ligand used in neuroimaging.

174 ter are routinely employed for prediction of PK profiles and drug interactions during drug developmen

175 ntitative in-vitro-to-in-vivo translation of PK and PD parameters and the prediction of drug absorpti

176 With understanding of PK/PD relationships, a target profile balancing TYK2 pot

177 placebo), and 9.9 (95% CI, 6.7-13.0) for OM-PK (P=0.03 versus placebo); for the Physical Limitation

178 (P=0.19), and 7.0 (95% CI, 4.1-10.0) for OM-PK (P=0.14).

179 g (P=0.12), and 4.3 (95% CI, 0.7-7.9) for OM-PK (P=0.42); for the Clinical Summary Score, it was 4.1

180 reduced ejection fraction assigned to the OM-PK group relative to placebo.

181 harmacokinetically guided dose titration (OM-PK) for 20 weeks.

182 ion types were obtained according to optimal PK sampling schema from 15 patients (10 men, 5 women, ag

183 erwent DMEK (121 eyes), DSAEK (423 eyes), or PK (405 eyes) from the prospective cohort from the Singa

184 ns the case in favor of performing DALK over PK when possible.

185 various geographical sources i.e. Pakistan (PK), Saudi Arabia (SA) and India (I).

186 g infusion pumps and inform on inter-patient PK variability, a step towards precise and personalized

187 in and an understandable pharmacokinetic/PD (PK/PD) relationship.

188 de is a new polyketide-nonribosomal peptide (PK-NRP) hybrid marine natural product isolated from Stre

189 population pharmacokinetic/pharmacodynamic (PK/PD) simulation model including rifampin, isoniazid, p

190 opulation pharmacokinetics/pharmacodynamics (PK/PD) and systems biology/pharmacology.

191 Pharmacokinetic (PK) parameters and receptor expressions were determined

192 s safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) effects of single BIIB059 d

193 orable pharmacodynamics and pharmacokinetic (PK) parameters, including substantial oral bioavailabili

194 end points were safety and pharmacokinetic (PK) variables.

195 eptor.drug antagonism or by pharmacokinetic (PK) approaches that seek to reduce the concentration of

196 development is establishing pharmacokinetic (PK) similarity, which is partly due to the degree of PK

197 Factor VIII (FVIII) pharmacokinetic (PK) properties show high interpatient variability in hem

198 pound 84 also showed a good pharmacokinetic (PK) profile in mice after IP dosing with compound exposu

199 mmunoaffinity (IA) LC-MS/MS pharmacokinetic (PK) assays are widely used in the field for antibody dru

200 esulting in attractive oral pharmacokinetic (PK) properties and improved TLR8 binding affinity.

201 uring the targeted potency, pharmacokinetic (PK), and toxicological profiles.

202 standing a drug candidate's pharmacokinetic (PK) parameters is a challenging but essential aspect of

203 a novel candidate drug, the pharmacokinetic (PK) behavior of the drug in humans is predicted from pre

204 of rapid PDT effects on the pharmacokinetic (PK) profiles of the released PTX.

205 livery - we investigate the pharmacokinetic (PK)-pharmacodynamic (PD) relationships that underlie the

206 d the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and behavioral effects of a no

207 Robust in vivo pharmacokinetic (PK) properties and tolerability mark these inhibitors as

208 able data on antimicrobial pharmacokinetics (PK) at infection sites hinders efforts to optimize antim

209 lso demonstrated excellent pharmacokinetics (PK) profile (high oral bioavailability and low clearance

210 and 51 showed a favorable pharmacokinetics (PK) profile across different species and robust efficacy

211 Here, plasma pharmacokinetics (PK) data of the OPTILIV trial in which cancer patients r

212 to characterize the plasma pharmacokinetics (PK) of cannabinoids and their metabolites in cattle afte

213 in Ewing sarcoma, but poor pharmacokinetics (PK) and toxicity limit its clinical use.

214 oteases, and a preclinical pharmacokinetics (PK) profile consistent with bid dosing in patients.

215 and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic

216 itro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compou

217 (betaCAB) and examined the pharmacokinetics (PK) in Sprague-Dawley rats for 3 months in comparison to

218 l were determined, and the pharmacokinetics (PK) of a 30-mg oral dose of PQ was measured in 45 volunt

219 We describe the pharmacokinetics (PK) of dolutegravir (DTG) 50 mg once daily in PLWH aged

220 The pharmacokinetics (PK) of endothelial surface-targeted affinity ligands and

221 lter drug disposition, the pharmacokinetics (PK), and biodistribution of acetaminophen were assessed

222 This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), clinical efficacy and safety

223 characterization of their pharmacokinetics (PK) and catabolism in both preclinical and clinical sett

224 This pharmacokinetics (PK) study assessed DMPA among HIV/TB coinfected women on

225 ) on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the human anti-C5 mono

226 nthly injections, variable pharmacokinetics (PK) between patients and various adverse reactions neces

227 Improved in vivo pharmacokinetics (PK) for the cabazitaxel (CBTX) NDCs with glycinate-conta

228 Analyses of drug pharmacokinetics (PKs) and pharmacodynamics (PDs) performed in animals are

229 tween drug concentrations (pharmacokinetics, PK), including in breastmilk, and impact on viral suppre

230 lysis of vitamin K compounds: phylloquinone (PK) and menaquinones (MK-n).

231 tification by LC-ESI-MS/MS of phylloquinone (PK), menaquinone-4 (MK-4), menaquinone-7 (MK-7) and mena

232 Here, we show that physiological PK modelling of first-pass drug absorption, metabolism a

233 The plasma PK profile suggests PQ metabolism is decreased in person

234 Natural product classes include polyketides (PKs), nonribosomal peptides (NRPs), and ribosomally synt

235 l follow-up was significantly higher in post-PK endophthalmitis (P = .02).

236 ent anti-HBV activity, favorable preclinical PK/PD profiles, and no early safety flags.

237 odel was assessed by comparing the predicted PK profiles and parameters with the observed data from p

238 ally linked two-channel organ chips-predicts PK parameters for orally administered nicotine (using gu

239 Prekallikrein (PK) is the precursor of the trypsin-like plasma protease

240 roteins factor XII (FXII) and prekallikrein (PK) undergo reciprocal activation to the proteases FXIIa

241 omposed of factor XII (FXII), prekallikrein (PK), and cofactor high-molecular-weight kininogen (HK).

242 Levels of plasma prekallikrein (PK), the precursor of KK, were markedly enhanced in acti

243 A total of 1,206 primary PKs were performed.

244 d PD modelling does not provide quantitative PK parameters.

245 , and protein kinase leucine-rich receptors (PK-LRR).

246 Recombinant PK that cannot be converted to PKa was prepared by repla

247 g growth and expression analyses of relevant PK mutants, we show that PykA is the dominant isoform in

248 hese novel analogues possess enhanced rodent PK, while also maintaining good mGlu(2) NAM potency, sel

249 om a monocyclic mGlu(2) NAM with poor rodent PK led to two novel heterobicyclic series of mGlu(2) NAM

250 ellular signal-regulated kinase-ribosomal S6 PK-phosphoinositide-dependent kinase (ERK-RSK-PDK) compl

251 ith alanine at the activation cleavage site (PK-R371A, or single-chain PK).

252 -treatment week 12 (SVR12), and steady-state PK by cirrhosis status.

253 Steady-state PK parameters were compared to a published historical co

254 Stochastic PK/pharmacodynamic (PD) simulations were carried out to

255 well tolerated in mice, displays substantial PK improvements over both vancomycin and CBP-vancomycin,

256 to maximizing the probability of successful PK predictions so that 83% of AstraZeneca drug developme

257 In the presence of a surface, PK-R371A converts FXII to FXIIa with a specific activity

258 used before tesidolumab affected tesidolumab PK and PD, resulting in a shortened period of full compl

259 Our study demonstrates that PK is an important direct regulator of BBB integrity as

260 with previous studies, our results show that PK-11195 does not dissociate directly into the solvent b

261 etween the MCD (8.34 +/- 2.12 mm Hg) and the PK (8.66 +/- 1.66 mm Hg) groups (P = .89); however, both

262 e interface between the P1 extension and the PK helix.

263 Meanwhile, CCT was comparable between the PK and control groups (P = .98).

264 paraquat, and heparin anti-coagulants by the PK approach.

265 participants enrolled, and 40 completed the PK phase.

266 n the MCD group (423 +/- 47 mmu) than in the PK group (541 +/- 31 mmu; P < .001) and the controls (54

267 accumulation, which was accounted for in the PK/PD model with increased tumor influx and efflux rates

268 es the folded conformation that includes the PK helix, so occluding the ribosome binding site and thu

269 riboswitch is largely unfolded, lacking the PK helix so that translation can be initiated at the rib

270 resent bioanalytical characterization of the PK and catabolism of a novel ADC.

271 ly, this work provides an examination of the PK-PD relationship governing STING activation upon syste

272 The electrophoretic pattern of the PK-resistant core of the spontaneous prion (Delta(Spont)

273 Clustering patients according to their PK parameter values revealed patient subgroups for each

274 This PK/PD model adequately describes the CPT anti-PDX tumor

275 tM2-PK enzyme was measured using two separate ScheBo-Biotech

276 alue of 4 U/ml, the sensitivity of fecal tM2-PK test was 100% and the specificity was 68%, and in the

277 Tumor pyruvate kinase M2 isoform (tM2-PK), which is an isoform of PK-glycolytic enzyme and app

278 ecommended in plasma samples, suggesting tM2-PK test as a non-invasive assay to diagnose CRC and aden

279 he aim of this study was to evaluate the tM2-PK measurement test for the diagnosis of CRCs and adenom

280 e Descemet perforation and the conversion to PK in a multi-surgeon setting.

281 Conversion to PK increased the risk of transplant rejection (P = .026;

282 Intraoperative conversion to PK was carried out in 2 of 58 (3.4%) F-DALK cases compar

283 re possible, may be safer than conversion to PK.

284 ten able to be managed without conversion to PK.

285 upport the notion that activity intrinsic to PK and FXII can initiate reciprocal activation of FXII a

286 Crucial for obtaining the ultralong PK profile was also a significant reduction of insulin r

287 in patients with MCD and in those undergoing PK for this stromal dystrophy.

288 led 24 eyes with MCD, 25 eyes that underwent PK in patients with preoperative diagnosis of MCD, and 2

289 Patients who underwent PK developed more complications of glaucoma (29.3% vs. 1

290 of drug PKs and PDs in humans, and in vitro PK and PD modelling does not provide quantitative PK par

291 ), demonstrated optimal and improved in vivo PK (plasma and tumor) and efficacy profile versus those

292 tro drug-target residence times, and in vivo PK properties, to identify first-in-class inhibitors tha

293 In vivo PK studies revealed that inhibitor 19 had moderate CNS p

294 te of graft rejection (1.7% vs DSAEK 5.0% vs PK 14.1%, P < .001) and postoperative elevation of intra

295 ntraocular pressure (11.6% vs DSAEK 23.6% vs PK 22.5%, P = .015).

296 cted by these Markov state models occur when PK-11195 is already in the membrane and involves only mi

297 nt study was undertaken to determine whether PK expresses similar activity.

298 that may initiate reciprocal activation with PK.

299 and significantly lower for EK compared with PK.

300 of biotransformation product formation with PK-PD modulation, and end with a discussion around safet